AstraZeneca PLC (LON:AZN – Get Free Report)’s stock price dropped 9% on Monday . The company traded as low as £114.14 and last traded at £115. 11,511,431 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 29,523,875 shares. The stock had previously closed at £126.32.
Wall Street Analyst Weigh In
AZN has been the topic of a number of research analyst reports. Citigroup raised their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Monday. Finally, Berenberg Bank reiterated a “buy” rating and set a £160 price target on shares of AstraZeneca in a research report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £152.17.
Get Our Latest Stock Report on AZN
AstraZeneca Price Performance
AstraZeneca Company Profile
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Featured Articles
- Five stocks we like better than AstraZeneca
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
